Centrient Pharmaceuticals* awarded second independent Minimized Risk of Antimicrobial Resistance (AMR) certification for Toansa, India Site

• Centrient continues to be a leader in the industry in minimizing the risk of antimicrobial resistance (AMR), actively shaping and meeting the independent standards now adopted across the sector
• Following our pioneering role at Santa Perpetua, Centrient’s Toansa site is the second to achieve BSI certification for responsible antibiotic manufacturing, setting a new benchmark for product-level compliance

Centrient Pharmaceuticals has earned its second Minimized Risk of Antimicrobial Resistance (AMR) Kitemark certificate from the British Standards Institute (BSI), awarded for the production of Purimox at the Lotus manufacturing plant in Toansa, India. This certification, based on the AMR Industry Alliance standard, follows Centrient’s pioneering certification at Santa Perpetua, Spain in 2024, and reinforces the company’s leadership in implementing rigorous antibiotic waste controls across multiple manufacturing sites.

The BSI Minimized Risk of AMR certificate is internationally recognized for its rigorous criteria. By ensuring that antibiotic residues are minimised and responsibly managed, the certification helps curb the spread of antimicrobial resistance—one of the largest global public health threats, according to the World Health Organization. This independent verification not only safeguards the efficacy of antibiotics for future generations, but also demonstrates Centrient’s commitment to sustainable, compliant manufacturing practices that support resilient healthcare supply chains.

“This certification is a testament to our team’s dedication and Centrient’s industry leadership,” says Centrient’s Chief Technical Operations Officer, Vesna Kapelj. “It demonstrates that sustainable, responsible antibiotic manufacturing is achievable at scale. By meeting and helping to define international standards, we are driving the transformation needed to protect antibiotics and public health for future generations.”

The Toansa site passed the BSI audit with no observations, demonstrating robust compliance and operational excellence. Three improvement opportunities were noted and will be integrated into our continuous improvement program.

As a founding member of the AMR Industry Alliance, Centrient continues to collaborate with regulators and industry partners to advance global standards. The BSI Kitemark for Minimized Risk of AMR provides independent verification that antibiotic waste streams are responsibly managed, safeguarding the efficacy of antibiotics worldwide. 

The company’s fifth consecutive gold EcoVadis rating in 2024 and ongoing commitment to ESG excellence—including targeted initiatives to combat antimicrobial resistance (AMR), further reinforces its reputation as a trusted partner for sustainable healthcare supply chains.

The company remains committed to expanding its leadership in AMR risk minimisation and setting new standards for the industry.

About BSI 

BSI, a business improvement and standards company, launched the BSI Kitemark for minimized risk of antimicrobial resistance certification programme to ensure that companies protect the efficacy of antibiotics for future generations. The certification follows the Antibiotic Manufacturing Standard, established by the AMR IA, to allow for independent third-party verification that waste streams containing antibiotic APIs and drug products are appropriately controlled during manufacturing by pharmaceutical companies. 

------------------------------------------------------------------------------------------------------------

About Centrient Pharmaceuticals

Centrient Pharmaceuticals[MS1]  is the global business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals. We are a pharmaceutical company with a clear Purpose: to improve lives through innovative and sustainable manufacturing of medicines - saving the lives of millions of people around the world annually. Regarding our portfolio, we produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as finished dosage forms (FDFs). Centrient Pharmaceuticals is a Board Member of the AMR Industry Alliance and a long-time advocate for industry responsibility in manufacturing. 

For more information, please visit www.centrient.com, www.linkedin.com/company/centrient or contact Centrient Pharmaceuticals Director of Global Communications and ESG, Neil Moorhouse. E-Mail: neil.moorhouse@centrient.com.

*( 1) “Centrient Pharmaceuticals”, “Centrient” in this content are sometimes used for convenience where references are made to Centrient International Pharmaceuticals B.V, and or one or more of its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Centrient Pharmaceuticals International B.V. and or one or more of its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. “Subsidiaries”, “Centrient subsidiaries” and “Centrient companies” as used in this content refer to entities over which Centrient Pharmaceuticals International B.V. either directly or indirectly has control. The term “Centrient interest” is used for convenience to indicate the direct and/or indirect ownership interest held by Centrient Pharmaceuticals International B.V. in an entity or unincorporated joint arrangement, after exclusion of all third-party interest.